PMID- 18208402
OWN - NLM
STAT- MEDLINE
DCOM- 20080820
LR  - 20111117
IS  - 1470-8736 (Electronic)
IS  - 0143-5221 (Linking)
VI  - 115
IP  - 5
DP  - 2008 Sep
TI  - Postprandial paradoxical IGFBP-1 response in obese patients with Type 2 diabetes.
PG  - 167-74
LID - 10.1042/CS20070372 [doi]
AB  - IGFs (insulin-like growth factors), which in an unbound form induce glucose and 
      amino acid uptake, circulate bound to IGFBPs (IGF-binding proteins), which 
      modulate their bioavailability and activity. The aim of the present study was to 
      examine the effect of a standard meal [2301 kJ (550 kcal)] on the serum levels of 
      IGFBP-1 in obese patients with T2DM (Type 2 diabetes mellitus), non-obese 
      patients with T1DM (Type 1 diabetes mellitus) and healthy controls, using the 
      artificial pancreas (Biostator) to obtain a normal glycaemic response to the 
      meal. IGFBP-1 levels decreased by 50% over 2 h following the meal at a similar 
      clearance in both the healthy controls and patients with T1DM, but no significant 
      decline was seen in the patients with T2DM, despite a several-fold increase in 
      insulin levels. The patients with T2DM were also studied during Sandostatin 
      (somatostatin) infusion to decrease the inappropriate secretion of glucagon 
      during the meal. During the 210 min of somatostatin infusion, the glucagon 
      response was suppressed and IGFBP-1 levels were increased concomitantly with the 
      peak in insulin levels, without any significant decrease after the meal. In 
      conclusion, the impaired IGFBP-1 response to meal-related hyperinsulinaemia in 
      obese patients with T2DM suggests a decreased availability of active IGF-1, 
      leading to a decrease in glucose uptake during and after a meal in these 
      patients. The stimulated meal response to glucagon, which contributes to 
      postprandial hyperglycaemia, could not explain the increase in serum IGFBP-1 in 
      these obese patients with T2DM.
FAU - Lehtihet, Mikael
AU  - Lehtihet M
AD  - Department of Internal Medicine, Karolinska Institutet, Stockholm South Hospital, 
      SE-118 83 Stockholm, Sweden. mikael.lehtihet@sodersjukhuset.se
FAU - Efendic, Suad
AU  - Efendic S
FAU - Brismar, Kerstin
AU  - Brismar K
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Clin Sci (Lond)
JT  - Clinical science (London, England : 1979)
JID - 7905731
RN  - 0 (Blood Glucose)
RN  - 0 (Insulin)
RN  - 0 (Insulin-Like Growth Factor Binding Protein 1)
RN  - 51110-01-1 (Somatostatin)
RN  - 9007-92-5 (Glucagon)
SB  - IM
MH  - Adult
MH  - Blood Glucose/drug effects/metabolism
MH  - Diabetes Mellitus, Type 1/blood
MH  - Diabetes Mellitus, Type 2/*blood
MH  - Female
MH  - Glucagon/blood
MH  - Humans
MH  - Insulin/blood
MH  - Insulin-Like Growth Factor Binding Protein 1/*blood
MH  - Male
MH  - Middle Aged
MH  - Obesity/*blood
MH  - Postprandial Period
MH  - Somatostatin/pharmacology
EDAT- 2008/01/23 09:00
MHDA- 2008/08/21 09:00
CRDT- 2008/01/23 09:00
PHST- 2008/01/23 09:00 [pubmed]
PHST- 2008/08/21 09:00 [medline]
PHST- 2008/01/23 09:00 [entrez]
AID - CS20070372 [pii]
AID - 10.1042/CS20070372 [doi]
PST - ppublish
SO  - Clin Sci (Lond). 2008 Sep;115(5):167-74. doi: 10.1042/CS20070372.